EA
AIMT

Emerald Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Emerald Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-525,423
Closed -$8.78M – 372
2020
Q2 		$8.78M Sell
525,423
-1,727
-0.3% -$29.3K 0.38% 93
2020
Q1 		$7.6M Sell
527,150
-82,373
-14% -$2.11M 0.44% 86
2019
Q4 		$20.4M Sell
609,523
-988
-0.2% -$27.6K 0.86% 42
2019
Q3 		$12.8M Sell
610,511
-230,020
-27% -$4.7M 0.6% 68
2019
Q2 		$17.5M Sell
840,531
-12,460
-1% -$257K 0.7% 54
2019
Q1 		$19.1M Buy
852,991
+111,245
+15% +$2.62M 0.78% 50
2018
Q4 		$17.7M Buy
741,746
+255,080
+52% +$6.6M 0.87% 46
2018
Q3 		$13.3M Buy
486,666
+36,230
+8% +$1.02M 0.49% 92
2018
Q2 		$12.1M Sell
450,436
-8,204
-2% -$251K 0.46% 97
2018
Q1 		$14.6M Sell
458,640
-9,473
-2% -$333K 0.59% 76
2017
Q4 		$17.7M Sell
468,113
-73,922
-14% -$2.39M 0.68% 59
2017
Q3 		$13.4M Sell
542,035
-16,911
-3% -$365K 0.55% 75
2017
Q2 		$11.5M Sell
558,946
-24,620
-4% -$470K 0.48% 84
2017
Q1 		$12.7M Sell
583,566
-189,429
-25% -$3.89M 0.52% 79
2016
Q4 		$15.8M Buy
772,995
+308,631
+66% +$6.31M 0.67% 58
2016
Q3 		$6.96M Buy
464,364
+193,854
+72% +$2.62M 0.31% 114
2016
Q2 		$2.93M Buy
270,510
+450
+0.2% +$6.11K 0.14% 175
2016
Q1 		$3.66M Sell
270,060
-298
-0.1% -$4.65K 0.18% 151
2015
Q4 		$4.99M Buy
270,358
+229,218
+557% +$4.24M 0.24% 125
2015
Q3 		$1.04M Buy
+41,140
New +$962K 0.05% 249

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Advisers's AIMT Position: Q3 2020 in Review

Emerald Advisers sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 525,423 shares — an estimated $8.78M sold.

Emerald Advisers first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $20.4M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Emerald Advisers reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Emerald Advisers sold 525,423 Aimmune Therapeutics shares in Q3 2020, an estimated $8.78M.
  • Emerald Advisers first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
  • Emerald Advisers's Aimmune Therapeutics position peaked at $20.4M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Emerald Advisers's 13F filing for Q3 2020, filed 28 Oct 2020.